Prognoz qilingan narxning foydaga nisbati: coyatherapeutics.com (COYA)

Coya Therapeutics (COYA) kompaniyasining rasmiy ramzlari

Coya Therapeutics, Inc. (COYA) uchun kutilayotgan P/E ko'rsatkichi bozor konsensusini aks ettiradi, bunda 0.00 ushbu indikatorning joriy darajasidir. Ushbu narx harakati Coya Therapeutics, Inc. (COYA) kompaniyasining inqilobiy terapiya sohasida patent yetakchiligini qo'lga kiritishdagi kurashini tasdiqlaydi. Brendning tartibga soluvchi T-hujayralari borasidagi nufuzi og'ir neyrodegenerativ jarayonlarni sekinlashtirishga yordam beradi. Uning intellektual mulkining yuqori masshtablanuvchanligi tibbiy mahsulotlarni butun dunyo bo'ylab samarali takrorlash imkonini beradi.

COYA - Coya Therapeutics Forvard P/E multiplikatori 28.04.2023 - 17.11.2026 oraligʻida

Coya Therapeutics, Inc. (COYA) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- kompaniyaning birjadagi kapitallashuv ko'rsatkichlari:
Fundamental baholash:Coya Therapeutics
Coya tovar namunasi

Coya Therapeutics, Inc. (COYA) barqarorligini baholashda investorlar T-hujayra texnologiyasi patentlarining yuqori xarajatlarini klinik sinovlarning muvaffaqiyat ehtimoli bilan taqqoslab ko'rishlari kerak. GURU.Markets platformasida Coya Therapeutics, Inc. (COYA) uchun kutilayotgan P/E tendentsiyasini tahlil qilish joriy bozor kapitalizatsiyasining prognoz qilingan foyda miqdoriga nisbatini ochib beradi, bu esa qat'iy ilmiy va texnologik to'siqlar sharoitida aktivlarning kelajakdagi pul oqimlari nisbatan haddan tashqari qimmat baholanganligini aniqlashga yordam beradi.

Coya Therapeutics, Inc. (COYA) raqobatchilari

Forvard P/E multiplikatori BIIB|NBIX - Prognoz qilingan narx-foyda nisbati|Forvard P/E multiplikatori RGC (Regencell Bioscience Ltd)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati axsome.com (AXSM)|ACADIA Pharmaceuticals Inc - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Xenon Pharmaceuticals Inc.|Viking Therapeutics (VKTX) - Kelajakdagi narxning foydaga nisbati|Supernus Corp - Kelajakdagi narx-foyda multiplikatori|Prognoz qilingan narxning foydaga nisbati CPRX|Denali Therapeutics Inc. (DNLI) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Prognoz qilingan narxning foydaga nisbati HRMY (Harmony Corp)|BHVN - Prognoz qilingan narx-foyda nisbati|Kelajakdagi narxning foydaga nisbati Amylyx Pharmaceuticals, Inc. AMLX|Kelajakdagi narx-foyda multiplikatori TRVI|PRAX - Kelajakdagi narxning foydaga nisbati|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Anavex Life Sciences AVXL|CBLL: Forvard P/E multiplikatori|Prognoz qilingan narxning foydaga nisbati Prothena Corporation PLC|ALEC (alector.com) - Forvard P/E multiplikatori|Prognoz qilingan narxning foydaga nisbati Annexon, Inc. (ANNX)|Kelajakdagi narxning foydaga nisbati Omeros Corporation (OMER)|Neurogene Inc. - Narxning kelajakdagi foydaga nisbati|acimmune.com - Prognoz qilingan narxning foydaga nisbati|Forvard P/E multiplikatori Voyager Therapeutics Inc VYGR|NMRA - Kelajakdagi narxning foydaga nisbati|Forvard narx-foyda multiplikatori Scilex Holding Company (SCLX)|Tevogen Bio Holdings (TVGN) - Kelajakdagi narxning foydaga nisbati|Narxning kelajakdagi foydaga nisbati ACOG|Kelajakdagi narxning foydaga nisbati Cognition Therapeutics, Inc.|Inhibikase Therapeutics, Inc. - Narxning kutilayotgan foydaga nisbati|Prognoz qilingan narxning foydaga nisbati SAVA (Cassava)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Assertio Therapeutics|Vistagen - Prognoz qilingan narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori OVID|Acumen Pharmaceuticals Inc. - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati CervoMed Inc|ATHE: Forvard P/E multiplikatori|Prognoz qilingan narxning foydaga nisbati Clene Nanomedicine|Kelajakdagi narxning foydaga nisbati PepGen Corp|Jupiter Neurosciences (JUNS) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Relmada Therapeutics, Inc. (RLMD)|ANVS - Prognoz qilingan narx-foyda nisbati|gracetx.com - Prognoz qilingan narxning foydaga nisbati|AIFF: Narxning kelajakdagi foydaga nisbati|Klotho Neurosciences - Forvard P/E multiplikatori|NRSN (NeuroSense Therapeutics Ltd.) - Narxning kelajakdagi foydaga nisbati|Reviva Pharmaceuticals (RVPH) - Kelajakdagi narxning foydaga nisbati|MTVA (MetaVia Inc.) - Kelajakdagi narxning foydaga nisbati|Kelajakdagi narxning foydaga nisbati NeurAxis, Inc|Kelajakdagi narxning foydaga nisbati HSDT|Forvard P/E multiplikatori PASG|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Prognoz qilingan narxning foydaga nisbati|Forvard P/E multiplikatori Athira ATHA|Addex Therapeutics - Forvard P/E multiplikatori|ALZN - Forvard P/E multiplikatori|Cyclerion (CYCN) - Kelajakdagi narxning foydaga nisbati|Protagenic (PTIX) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Pasithea|Narxning kelajakdagi foydaga nisbati CRGT (Cortigent)|Kelajakdagi narxning foydaga nisbati Avenue Therapeutics (ATXI)|BCLI - Prognoz qilingan narx-foyda nisbati|Forvard P/E multiplikatori CARA (Cara Therapeutics Inc)|CHRO - Prognoz qilingan narxning foydaga nisbati|ELYM: Prognoz qilingan narxning foydaga nisbati|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Kelajakdagi narxning foydaga nisbati|Marinus - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati NKGen Biotech Inc|NRBO: Kelajakdagi narx-foyda multiplikatori|Prognoz qilingan narxning foydaga nisbati SAGE (Sage Therapeutics, Inc.)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Neurotrope|Kelajakdagi narxning foydaga nisbati Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Prognoz qilingan narx-foyda nisbati|WENA: Prognoz qilingan narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori CERE (Cerevel Therapeutics)